Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Geyer, Holly L ^a   Dueck, Amylou C ^a   Scherber, Robyn M ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN; C REACTIVE PROTEIN; FEDRATINIB; GANDOTINIB; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; MOMELOTINIB; PACRITINIB; PEGINTERFERON; PENTRAXIN; RANTES; RUXOLITINIB; STAT3 PROTEIN; STEROID; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT; CYTOKINE;

BONE PAIN; CACHEXIA; CHRONIC INFLAMMATION; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; FATIGUE; FEVER; GENOMIC INSTABILITY; HUMAN; MYELOPROLIFERATIVE NEOPLASM; NIGHT SWEAT; NONHUMAN; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SEDENTARY LIFESTYLE; SIGNAL TRANSDUCTION; SOCIAL STATUS; SPLENOMEGALY; SYMPTOM; WEIGHT REDUCTION; ANIMAL; COGNITIVE DEFECT; COMPLICATION; DISEASE COURSE; INFLAMMATION; METABOLISM; MICROCIRCULATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; POLYCYTHEMIA VERA; SYMPTOM ASSESSMENT; THROMBOCYTHEMIA; TREATMENT OUTCOME;

ANIMALS; COGNITION DISORDERS; CYTOKINES; DISEASE PROGRESSION; FATIGUE; HUMANS; INFLAMMATION; MICROCIRCULATION; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PRURITUS; SPLENOMEGALY; SYMPTOM ASSESSMENT; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME;

EID: 84946042291     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/284706     Document Type: Review

References (68)

1. F. Cervantes, B. Dupriez, A. Pereira et al., "New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment, " Blood, vol. 113, no. 13, pp. 2895-2901, 2009.
2. N. Gangat, D. Caramazza, R. Vaidya et al., "DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status, " Journal of Clinical Oncology, vol. 29, no. 4, pp. 392-397, 2011.
3. R. Scherber, A. C. Dueck, P. Johansson et al., "The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients, " Blood, vol. 118, no. 2, pp. 401-408, 2011.
4. R. Mesa, C. B. Miller, M. Thyne et al., "Impact of myeloproliferative neoplasms (MPNs) on patients' overall health and productivity: results from the MPN LANDMARK SURVEY in the United States, " Blood, vol. 124, no. 21, p. 3183, 2014.
5. H. Geyer, A. C. Dueck, R. M. Emanuel et al., "Insomnia, quality of life and MPN symptom burden: An analysis by the MPN quality of life international study group (MPN-QOL ISG), " Blood, vol. 122, no. 21, p. 4087, 2013.
6. H. Geyer, A. C. Dueck, R. M. Emanuel et al., "Sexuality challenges, intimacy, andMPN symptomburden: An analysis by the MPN quality of life international study group (MPN-QOL ISG), " Blood, vol. 122, p. 4088, 2013.
7. H. L. Geyer, R. M. Scherber, A. C. Dueck et al., "Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients, " Blood, vol. 123, no. 24, pp. 3803-3810, 2014.
8. R. A. Mesa, J. Niblack, M. Wadleigh et al., "The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet-based survey of 1179 MPD patients, " Cancer, vol. 109, no. 1, pp. 68-76, 2007.
9. R. A. Mesa, S. Schwager, D. Radia et al., "The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment inmyelofibrosis, " Leukemia Research, vol. 33, no. 9, pp. 1199-1203, 2009.
10. R. A. Mesa, H. Kantarjian, A. Tefferi et al., "Evaluating the serial use of themyelofibrosis symptom assessment form formeasuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial, " Cancer, vol. 117, no. 21, pp. 4869-4877, 2011.
11. S. Verstovsek, R. A. Mesa, S. K. Rhoades et al., "Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients withmyelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), " Blood, vol. 118, pp. 1213-1214, 2011.
12. S. Verstovsek, R. A. Mesa, J. Gotlib et al., "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, " The New England Journal of Medicine, vol. 366, no. 9, pp. 799-807, 2012.
13. C. L. Andersen, N. B. Mortensen, T. W. Klausen, H. Vestergaard, O. W. Bjerrum, and H. C. Hasselbalch, "A phase ii study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia veramyelofibrosis, " Haematologica, vol. 99, no. 1, pp. e5-e7, 2014.
14. R. M. Emanuel, A. C. Dueck, H. L. Geyer et al., "Myeloproliferative neoplasm (MPN) symptomassessment formtotal symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs, " Journal of Clinical Oncology, vol. 30, no. 33, pp. 4098-4103, 2012.
15. R. L. Levine, M. Wadleigh, J. Cools et al., "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, andmyeloidmetaplasia withmyelofibrosis, " Cancer Cell, vol. 7, no. 4, pp. 387-397, 2005.
16. A. L.-F. Mui, "Therole of STATs in proliferation, differentiation, and apoptosis, " Cellular and Molecular Life Sciences, vol. 55, no. 12, pp. 1547-1558, 1999.
17. H. C. Hasselbalch, "Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?" Blood, vol. 119, no. 14, pp. 3219-3225, 2012.
18. C. A. Dinarello, "Historical insights into cytokines, " European Journal of Immunology, vol. 37, supplement 1, pp. S34-S45, 2007.
19. M. E. Figueroa, O. Abdel-Wahab, C. Lu et al., "Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, " Cancer Cell, vol. 18, no. 6, pp. 553-567, 2010.
20. H. Frederiksen, D. K. Farkas, C. F. Christiansen, H. C. Hasselbalch, and H. T. Sørensen, "Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study, " Blood, vol. 118, no. 25, pp. 6515-6520, 2011.
21. H. C. Hasselbalch, "Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?" Leukemia Research, vol. 37, no. 2, pp. 214-220, 2013.
22. H. C. Hasselbalch, "Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism, " Danish Medical Bulletin, vol. 40, no. 1, pp. 39-55, 1993.
23. A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho, and A. Pardanani, "Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primarymyelofibrosis: A comprehensive cytokine profiling study, " Journal of Clinical Oncology, vol. 29, no. 10, pp. 1356-1363, 2011.
24. A. C. Dueck, C. S. Cleeland, R. Dantzer et al., "Cytokine profile changes in 309 myelofibrosis patients: comparison of JAK1/ JAK2 inhibitor therapy vs. placebo-correlative analysis from the comfort-I trial, " Blood, vol. 122, no. 21, p. 4074, 2013.
25. R. Vaidya, N. Gangat, T. Jimma et al., "Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis, " American Journal of Hematology, vol. 87, no. 11, pp. 1003-1005, 2012.
26. E. Pourcelot, C. Trocme, J. Mondet, S. Bailly, B. Toussaint, and P. Mossuz, "Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications, " Experimental Hematology, vol. 42, no. 5, pp. 360-368, 2014.
27. L. Catani, L. Rossi, D. Sollazzo et al., "Crucial factors of the inflammatory microenvironment promote maintenance of the malignant hemopoietic clone of myelofibrosis by stimulating survival and inhibiting proliferation of CD34+ stem/progenitor cells, " Blood, vol. 124, no. 21, p. 3220, 2014.
28. T. Barbui, A. Carobbio, G. Finazzi et al., "Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3, " Haematologica, vol. 96, no. 2, pp. 315-318, 2011.
29. S.-Y. Yoon, C.-Y. Li, R. V. Lloyd, and A. Tefferi, "Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders, " International Journal of Hematology, vol. 72, no. 3, pp. 337-342, 2000.
30. M. C. Le Bousse-Kerdilès andM. C. Martyré, "Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis, " Annals of Hematology, vol. 78, no. 10, pp. 437-444, 1999.
31. O. Bock, J. Höftmann, K. Theophile et al., "Bone morphogenetic proteins are overexpressed in the bone marrow of primarymyelofibrosis and are apparently induced by fibrogenic cytokines, " American Journal of Pathology, vol. 172, no. 4, pp. 951-960, 2008.
32. A. Tabarroki, H. Rogers, V. Visconte et al., "The molecular and cytokine profile of triple-negative (JAK2 V617F, JAK2 exon 12, MPL negative) myelofibrosis, amyeloproliferative neoplasm with distinct clinico-pathologic characteristics, " Blood, vol. 633, p. 3805, 2012, ASHAnnual Meeting.
33. D. P. Lawrence, B. Kupelnick, K. Miller, D. Devine, and J. Lau, "Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients, " Journal of the National Cancer Institute. Monographs, no. 32, pp. 40-50, 2004.
34. J. E. Bower, P. A. Ganz, M. R. Irwin, L. Kwan, E. C. Breen, and S. W. Cole, "Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?" Journal of Clinical Oncology, vol. 29, no. 26, pp. 3517-3522, 2011.
35. R. Kurzrock, "The role of cytokines in cancer-related fatigue, " Cancer, vol. 92, no. 6, pp. 1684-1688, 2001.
36. C. A. Meyers, M. Albitar, and E. Estey, "Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome, " Cancer, vol. 104, no. 4, pp. 788-793, 2005.
37. J. E. Bower, P. A. Ganz, N. Aziz, R. Olmstead, M. R. Irwin, and S. W. Cole, "Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids, " Brain, Behavior, and Immunity, vol. 21, no. 3, pp. 251-258, 2007.
38. J. E. Bower, P. A. Ganz, K. A. Desmond et al., "Fatigue in longterm breast carcinoma survivors: A longitudinal investigation, " Cancer, vol. 106, no. 4, pp. 751-758, 2006.
39. D. L. Musselman, A. H. Miller, M. R. Porter et al., "Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings, " American Journal of Psychiatry, vol. 158, no. 8, pp. 1252-1257, 2001.
40. R. M. Scherber, Z. Senyak, A. C. Dueck et al., "High prevalence of mood disorders in MPNs and their possible role in MPN related fatigue, " Blood, vol. 124, no. 21, p. 3173, 2014.
41. R. M. Scherber, Z. Senyak, A. C. Dueck et al., "The impact of medical comorbidities in MPN-related fatigue, " Blood, vol. 124, p. 1862, 2014.
42. J. Li, D. P. Sejas, X. Zhang et al., "TNF-induces leukemic clonal evolution ex vivo in Fanconi anemia groupCmurine stem cells, " Journal of Clinical Investigation, vol. 117, no. 11, pp. 3283-3295, 2007.
43. A. G. Fleischman, K. J. Aichberger, S. B. Luty et al., "TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms, " Blood, vol. 118, no. 24, pp. 6392-6398, 2011.
44. D. Wang, J. Yin, R. Dong et al., "Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats, " Digestive and Liver Disease, vol. 47, pp. 315-323, 2015.
45. L. R. Watkins and S. F. Maier, "The pain of being sick: implications of immune-to-brain communication for understanding pain, " Annual Review of Psychology, vol. 51, pp. 29-57, 2000.
46. N. Üçeyler, J. P. Rogausch, K. V. Toyka, and C. Sommer, "Differential expression of cytokines in painful and painless neuropathies, " Neurology, vol. 69, no. 1, pp. 42-49, 2007.
47. F. Shintani, S. Kanba, T. Nakaki et al., "Interleukin-1 augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus, " The Journal of Neuroscience, vol. 13, no. 8, pp. 3574-3581, 1993.
48. P. S. Mohankumar, S. Thygarajan, and S. K. Quadri, "Interleukin-1 stimulates the release of dopamine and dihydroxyphenylacetic acid from the hypothalamus in vivo, " Life Sciences, vol. 48, no. 9, pp. 925-930, 1991.
49. N. L. Sparkman, J. B. Buchanan, J. R. R. Heyen, J. Chen, J. L. Beverly, and R. W. Johnson, "Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampalneuronal cell layers, " The Journal of Neuroscience, vol. 26, no. 42, pp. 10709-10716, 2006.
50. C. N. Harrison, G. Barosi, A. M. Vannucchi et al., "The relationship between cytokine levels and symptoms in patients (Pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT), " Blood, vol. 122, no. 21, p. 4070, 2013.
51. K. S. Krabbe, A. Reichenberg, R. Yirmiya, A. Smed, B. K. Pedersen, and H. Bruunsgaard, "Low-dose endotoxemia and human neuropsychological functions, " Brain, Behavior, and Immunity, vol. 19, no. 5, pp. 453-460, 2005.
52. K. S. Krabbe, M. Pedersen, andH. Bruunsgaard, "Inflammatory mediators in the elderly, " Experimental Gerontology, vol. 39, no. 5, pp. 687-699, 2004.
53. F. Zipp and O. Aktas, "The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases, " Trends in Neurosciences, vol. 29, no. 9, pp. 518-527, 2006.
54. X. Jin, W. Zhao, A. Kirabo et al., "Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice, " Journal of Immunology, vol. 193, no. 2, pp. 477-484, 2014.
55. L. Pieri, C. Bogani, P. Guglielmelli et al., "The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera, " Haematologica, vol. 94, no. 11, pp. 1537-1545, 2009.
56. J. Wang, T. Ishii, W. Zhang et al., "Involvement of mast cells by the malignant process in patients with Philadelphia chromosomenegativemyeloproliferative neoplasms, " Leukemia, vol. 23, no. 9, pp. 1577-1586, 2009.
57. N. Jackson, D. Burt, J. Crocker, and B. Boughton, "Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus, " British Journal of Dermatology, vol. 116, no. 1, pp. 21-29, 1987.
58. J. F. Seymour, M. Talpaz, F. Cabanillas, M. Wetzler, and R. Kurzrock, "Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma, " Journal of Clinical Oncology, vol. 13, no. 3, pp. 575-582, 1995.
59. J. F. Seymour, M. Talpaz, F. B. Hagemeister, F. Cabanillas, and R. Kurzrock, "Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease, " The American Journal of Medicine, vol. 102, no. 1, pp. 21-28, 1997.
60. J. Cortes and R. Kurzrock, "Interleukin-10 in non-Hodgkin's lymphoma, " Leukemia & Lymphoma, vol. 26, no. 3-4, pp. 251-259, 1997.
61. E. J. B. Ramos, S. Suzuki, D. Marks, A. Inui, A. Asakawa, and M. M. Meguid, "Cancer anorexia-cachexia syndrome: cytokines and neuropeptides, " Current Opinion in Clinical Nutrition and Metabolic Care, vol. 7, no. 4, pp. 427-434, 2004.
62. J. M. Argilés, S. Busquets, and F. J. López-Soriano, "The pivotal role of cytokines inmusclewasting during cancer, " International Journal of Biochemistry and Cell Biology, vol. 37, no. 10, pp. 2036-2046, 2005.
63. M. J. Tisdale, "Biology of cachexia, " Journal of the National Cancer Institute, vol. 89, no. 23, pp. 1763-1773, 1997.
64. M. Bossola, M. Muscaritoli, P. Costelli et al., "Increased muscle ubiquitin mrna levels in gastric cancer patients, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 280, no. 5, pp. R1518-R1523, 2001.
65. B. Seruga, H. Zhang, L. J. Bernstein, and I. F. Tannock, "Cytokines and their relationship to the symptoms and outcome of cancer, " Nature Reviews Cancer, vol. 8, no. 11, pp. 887-899, 2008.
66. M. G. Flynn and B. K. McFarlin, "Toll-like receptor 4: link to the anti-inflammatory effects of exercise?" Exercise and Sport Sciences Reviews, vol. 34, no. 4, pp. 176-181, 2006.
67. H. M. Kvasnicka, J. Thiele, C. E. Bueso-Ramos et al., "Changes in activated bone marrow macrophages and mast cells in patients with myelofibrosis following ruxolitinib therapy, " Blood, vol. 124, no. 21, p. 3184, 2014.
68. J. Singer, S. Al-Fayoumi, H. Ma, R. S. Komrokji, R. Mesa, and S. Verstovsek, "Comprehensive kinase profile of pacritinib, a nonmyelosuppressive JAK2 kinase inhibitor in phase 3 development in primary and post ET/PV myelofibrosis, " Blood, vol. 124, no. 21, p. 1874, 2014.